FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

•Fluoropyrimidine-platinum doublets are the standard for advanced gastric cancer.•EGFR and HGF/MET pathways are often deregulated in advanced gastric cancer.•Panitumumab and rilotumumab are directed against EGFR and HGF, respectively.•Adding panitumumab to chemotherapy is ineffective in advanced gastric cancer.•Adding rilotumumab to chemotherapy is ineffective in advanced gastric cancer.